MetaCap

Cellectar Biosciences (CLRB) vs Lexaria Bioscience (LEXX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lexaria Bioscience is the larger company by market cap ($8.5 million vs $8.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CLRB-47.22%LEXX+16.47%
+39%-6%-51%
Oct 7, 20261 yearNov 20, 2026
CLRB-45.03%LEXX+21.39%
+40%-5%-49%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CLRB versus LEXX key metrics
MetricCLRBLEXX
Share price$0.797$4.03
Market cap$8.00M$8.49M
1-day change-11.50%-10.24%
YTD return-72.98%—
1-year return-72.13%—
5-year return-99.63%—
EPS (TTM)$-2.34$-5.10
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$705.92K
Revenue growth (YoY)—+52.05%
Net income (latest FY)$-21.79M$-11.90M
Gross margin—99.61%
Operating margin—-1683.01%
Net margin—-1686.00%
52-week high$4.70$21.60
52-week low$0.7596$2.43
Distance from 52-week high-83.04%-81.34%
Analyst consensusnonenone
Avg. price target upside+1342.91%+1947.15%
Average volume97.96K70.52K
Shares outstanding10.04M2.11M
Employees117
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Cellectar Biosciences

CLRB stock →

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees

About Lexaria Bioscience

LEXX stock →

Lexaria Bioscience Corp. operates as a biotechnology company.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

CLRB vs LEXX FAQ

Which is bigger, Cellectar Biosciences or Lexaria Bioscience?

Lexaria Bioscience (LEXX) is larger, with a market capitalization of $8.49M compared with $8.00M for Cellectar Biosciences (CLRB).

Are Cellectar Biosciences and Lexaria Bioscience in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons